Brief: Amylyx Pharmaceuticals Announces Formal Intention To Remove Relyvrio®/Albrioza™ From The Market

Amylyx Pharmaceuticals

04/04/2024 12:12

April 4 (Reuters) - Amylyx Pharmaceuticals Inc  AMLX.O :
    * AMYLYX PHARMACEUTICALS ANNOUNCES FORMAL INTENTION TO
REMOVE
RELYVRIO®/ALBRIOZA™ FROM THE MARKET; PROVIDES UPDATES ON ACCESS
TO THERAPY, PIPELINE, CORPORATE RESTRUCTURING, AND STRATEGY
    * AMYLYX PHARMACEUTICALS INC: RESTRUCTURING PLAN REDUCES
WORKFORCE
BY APPROXIMATELY 70%
    * AMYLYX PHARMACEUTICALS INC - EXTENDS EXPECTED CASH RUNWAY
INTO
2026
    * AMYLYX: CONTINUES TO ADVANCE AMX0035 IN WOLFRAM SYNDROME
AND IN
PROGRESSIVE SUPRANUCLEAR PALSY AND AMX0114 IN ALS
    * AMYLYX PHARMACEUTICALS INC - CONTINUE TO PLAN FOR AN
INTERIM
ANALYSIS TO EVALUATE DATA FROM ORION THAT IS NOW EXPECTED IN
MID-2025

Source text for Eikon:  ID:nBw3fJ9P0a 
Further company coverage:  AMLX.O 

 ((Reuters.Briefs@thomsonreuters.com;))